Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1236-1242

  Akamine, Eliana H ^a   Hohman, Thomas C ^b   Nigro, Dorothy ^a   Carvalho, Maria Helena C ^a   De Cássia Tostes, Rita ^a   Fortes, Zuleica B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALDOSE REDUCTASE INHIBITOR; ALLOXAN; BRADYKININ; CATAFLAN; DICLOFENAC; HISTAMINE; MINALRESTAT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POTASSIUM CHANNEL; PROSTAGLANDIN SYNTHASE; TETRYLAMMONIUM; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GALACTOSEMIA; HYPERPOLARIZATION; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GALACTOSEMIAS; IMIDES; MALE; QUINOLONES; RATS; RATS, WISTAR; SPLANCHNIC CIRCULATION; VASOCONSTRICTOR AGENTS;

EID: 0345382832     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044693     Document Type: Article

References (39)

1. American Diabetes Association (1993) Implications of the diabetes control and complications trial. Diabetes 42:1555-1558.
2. Baez S (1969) Simultaneous measurements of radii and wall thickness of microvessels in the anesthetized rat. Circ Res 25:315-329.
3. Boulton AJM, Levin S, and Comstock J (1990) A multicentre trial of the aldosereductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 33:431-437.
4. Brazzell RK, Mayer PR, Dobbs R, McNamara PJ, Teng R, and Slattery JT (1991) Dose-dependent pharmacokinetics of aldose reductase inhibitor imirestat in man. Pharm Res 1:112-118.
5. Cameron NE and Cotter MA (1992) Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia 35:1011-1019.
6. Cameron NE and Cotter MA (1993) Contraction and relaxation of aortas from galactosemic rats and the effects of aldose reductase inhibition. Eur J Pharmacol 243:47-53.
7. Cameron NE, Cotter MA, and Hohman TC (1996) Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia 39:172-182.
8. Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, and Larkins RG (1991) The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia 34:225-231.
9. Cruz JWMC, Oliveira MA, Hohman TC, and Fortes ZB (2000) Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 391:163-174.
10. De Vriese AS, Van de Voorde J, Blom HJ, Vanhoutte PM, Verbeke M, and Lameire NH (2000) The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia 43:1116-1125.
11. Dvornik D (1987) Hyperglycemia in the pathogenesis of diabetic complications, in Aldose Reductase Inhibition. Na Approach to the Prevention of Diabetic Complications (Porte D ed) pp 69-225, Biochemical Information Corporation, New York.
12. Félétou M and Vanhoutte PM (1999) The alternative: EDHF. J Mol Cell Cardiol 31:15-22.
13. Florkowski CW, Rowe BR, Nightingale S, Harvey TC, and Barnett AH (1991) Clinical and neurophysiologial studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 40:129-133.
14. Fortes ZB, Becker C, Oliveira MA, and Scivoletto (1996) Influence of aldose reductase inhibition on the microvascular reactivity in experimental diabetes. Gen Pharmacol 27:917-921.
15. Fortes ZB, Garcia-Leme J, and Scivoletto R (1983a) Influence of diabetes on the reactivity of mesenteric microvessels to histamine, bradykinin and acetylcholine. Br J Pharmacol 78:39-48.
16. Fortes ZB, Garcia-Leme J, and Scivoletto R (1983b) Vascular reactivity in diabetes mellitus: role of the endothelial cell. Br J Pharmacol 79:771-781.
17. Fortes ZB, Garcia-Leme J, and Scivoletto R (1984) Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 83:635-643.
18. Fortes ZB, Scivoletto R, and Garcia-Leme J (1989) Functional changes in the micro-circulation of alloxan-induced diabetic rats. Gen Pharmacol 20:615-620.
19. Fukao M, Hattori Y, Kanno M, Sakuma I, and Kitabatake A (1997) Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 121:1383-1391.
20. Fulton D, McGiff JC, and Quilley J (1996) Cytochrome P450 arachidonate metabolites: deficit in diabetes mellitus? FASEB J 9:A113.
21. Garcia-Leme J (1981) Regulatory mechanism in inflammation. New aspects of autopharmacology. Gen Pharmacol 12:15-24.
22. Garcia-Leme J (1989) The vascular response of injury, in Hormones and Inflammation, pp 130-139, CRC Press, Boca Raton, FL.
23. Garcia-Leme J, Böhm GM, Migliorini RH, and Souza MZA (1974) Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 29:298-306.
24. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukoto JM, and Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:843-850.
25. Kamijo M, Cherian PV, and Sima AAF (1993) The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat. Diabetologia 36:983-988.
26. Keegan A, Jack AM, Cotter MA, and Cameron NE (2000) Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats. J Cardiovasc Pharmacol 35:606-613.
27. Kinoshita JH, Kador P, and Robinson WG (1984) Aldose reductase and complications of diabetes. Ann Int Med 101:82-91.
28. Kirchain WR and Rendell MS (1990) Aldose reductase inhibitors. Pharmacotherapy 10:326-336.
29. Malamas MS, Hohman TC, and Millen J (1994) Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2- fluorophenyl)methyl]-6-fluorospiro[isoquinoline-4(1H), 3′-pyrrolidine]-1,2′,3,5′(2H)-tetrone and congeners. 1. J Med Chem 37:2043-2058.
30. Otter DJ and Chess-Williams R (1994) The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats. Br J Pharmacol 113:576-580.
31. Peredo HÁ, Feleder EC, and Adler-Graschinsky E (1999) Time-course of the alterations in prostanoid production and in contractile responses of mesenteric beds isolated from streptozotocin diabetic rats. Prostaglandins Leukot Essent Fatty Acids 60:269-274.
32. Pitts NE, Vreeland F, Shaw GL, Peterson MJ, Mehta DJ, Collie J, and Gundersen K (1986) Clinical experience with sorbinil - an aldose reductase inhibitor. Metabolism 35 (Suppl 1):96-100.
33. Quilley J, Fulton D, and McGiff JC (1997) Hyperpolarizing factors. Biochem Pharmacol 54:1059-1070.
34. Robison WG (1988) Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors. Adv Exp Med Biol 246:365-372.
35. Santiago JV (1993) Lessons from the diabetes control and complications trial. Diabetes 42:1549-1554.
36. Stribling D (1990) Clinical trials with aldose reductase inhibitors. Exp Eye Res 50:621-624.
37. Tesfamariam B, Palacino JJ, Weisbrod RM, and Cohen RA (1993) Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 21:205-211.
38. Tomlinson DR, Stevens EJ, and Diemel LT (1994) Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci 15:293-297.
39. Zweifach BW (1948) Indirect methods for regional blood flow. I. Microscopic observation of circulation in rat mesoappendix and dog omentum. Use in study of vasotropic substances. Methods Med Res 1:131-138.